everolimus
Not Tagged
['everest', 'rcc,(-irccs),(-srcc),(-urcc)']
 2022 : everest trial : everolimus vs placebo in adjuvant rcc : negative trial - benefit in rfs (primary endpoint) only for very high risk patients (55% of the pop) - 55% of patients discontinued treatment in the everolimus arm ! 
urologue à L'institut Paoli-Calmettes à Marseille